💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Fidelity boosted pre-IPO value of Twilio by 31 percent in November

Published 12/30/2015, 10:21 AM
Updated 12/30/2015, 10:30 AM
© Reuters. A pedestrian walks past a stock ticker at a Fidelity Investments office in Boston

By Tim McLaughlin

BOSTON (Reuters) - Fidelity Investments, one of the largest investors in pre-IPO companies, boosted the value of Twilio Inc by 31 percent in November, as speculation builds that the provider of mobile messaging platforms may go public in 2016.

Fidelity's $100 billion-plus Contrafund valued its Series E stake in Twilio at $43.5 million in November, compared with $33.2 million a month earlier, according to disclosures made public on Wednesday.

The Wall Street Journal has reported that San Francisco-based Twilio has filed confidentially for an initial public offering that could happen as soon as the first quarter of 2016. This past summer Twilio raised $130 million in a Series E funding round led by Boston-based Fidelity and T. Rowe Price Group Inc.

Fidelity funds are a good barometer of what is happening in the pre-IPO landscape because they disclose their holdings, and shifting valuations, on a monthly basis. Most mutual funds disclose their holdings quarterly.

Content marketing firm Taboola.com Ltd also got a valuation boost from Fidelity, according to disclosures on Wednesday. Fidelity's OTC Portfolio valued its Taboola stake at $13.6 million at the end of November, a 27 percent boost from a month earlier.

Portfolio managers at Fidelity do not set the pre-IPO values. That is done by a separate committee at Fidelity.

Nutanix Inc, which filed for an IPO earlier this month, saw its valuation fall 11 percent in Fidelity funds, according to Wednesday disclosures for end-of-November holdings.

© Reuters. A pedestrian walks past a stock ticker at a Fidelity Investments office in Boston

And Paris-based GenSight Biologics, which is developing therapies to fight eye disease, had its valuation cut by 44 percent at Fidelity in November. The biopharma pulled its plan for an IPO last month.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.